Related Experiment Video

Updated: Jun 25, 2026

Application of DNA Fingerprinting using the D1S80 Locus in Lab Classes
08:35

Application of DNA Fingerprinting using the D1S80 Locus in Lab Classes

Published on: July 17, 2021

Apolipoprotein AI and Apolipoprotein B gene polymorphisms and lipid profile in Tamilian population

N Padmaja1, M Ravindra Kumar, C Adithan

  • 1Pharmacogenomics Laboratory, Department of Pharmacology, Jawaharlal Institute of Post-graduate Medical Education and Research, Pondicherry, India. padmaja_25@yahoo.com

Annals of Human Biology
|February 5, 2009
PubMed

Apolipoprotein (ApoAI) is the major protein constituent of high density lipoproteins (HDL). Apolipoprotein (apo) B-100, a component of low density lipoprotein (LDL), serves as a ligand for the removal of LDL from the circulation by the LDL receptor. Genotyping of ApoAI and ApoB polymorphisms was carried out in 185 healthy Tamilian volunteers of south India after clinical examination. Lipid profile was estimated and polymorphisms were detected by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. The frequency of the rare M1-, M2- and R- alleles were 21%, 4.3% and 5.4%, respectively. An increase of 9.1 mg dL(-1) (0.23 mmol L(-1)) in HDL-cholesterol (HDL-C) levels was observed with M1-/- genotype when compared to M1+/+ genotype, which was not found after adjustments were made for confounding risk factors. A paradoxical increase in levels of total cholesterol and LDL-cholesterol (LDL-C) was observed with M2+/- genotype when compared to M2+/+ genotype. Analysis of combination of genotypes of ApoAI revealed no influence on the lipid parameters. ApoB EcoRI in contrast to ApoAI polymorphisms had no significant effect on lipid profile..

More Related Videos

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...